Last Update 18 Mar 26

Fair value Increased 17%

RHC: Revised Assumptions And Dividend Outlook Will Shape Future Share Performance

Analysts have lifted their price target on Ramsay Health Care from around A$37.09 to about A$43.33, citing updated assumptions on discount rates, revenue growth, profit margins and future P/E multiples following recent research, including a downgrade from Morgan Stanley.

Analyst Commentary

Bullish Takeaways

Bullish analysts view the lift in the consolidated price target to about A$43.33 as support for upside potential if Ramsay delivers on its revised revenue and margin assumptions.
Updated P/E multiples used in recent research suggest that some analysts still see room for valuation support if earnings hold close to current expectations.
Reworked discount rate inputs are seen by bullish analysts as better aligning the share price with perceived risk, which they argue makes the risk or reward trade off clearer for long term holders.
The continued detailed coverage, even alongside a downgrade, is interpreted by some as a signal that Ramsay remains a core name in its sector, with scope for sentiment to improve if execution is solid.

Bearish Takeaways

Bearish analysts highlight the recent downgrade at Morgan Stanley as a reminder that execution risk around revenue growth and profit margins is still front of mind.
Some remain cautious that the updated valuation work, including changes to discount rates and future P/E multiples, may already reflect a fair or full view of Ramsay's current outlook.
There is concern that any shortfall versus the revised assumptions on earnings could put pressure on the new A$43.33 price target and compress the implied upside from current levels.
Bearish analysts also point out that higher required returns embedded in some models, via adjusted discount rates, signal less willingness to pay up for execution or growth that is not yet clearly visible.

What’s in the News

Ramsay Health Care declared a dividend of A$0.425 per ordinary share for the six months ended 31 December 2025, giving investors clearer visibility on the timing of upcoming income. (Key Developments)
The dividend is scheduled to be paid on 26 March 2026, which is the date cash is expected to be distributed to eligible shareholders. (Key Developments)
The ex dividend date is 9 March 2026, meaning anyone buying shares on or after that date would typically not receive this dividend. (Key Developments)
The record date is 10 March 2026, which is the date the share register is used to determine who is entitled to the A$0.425 dividend. (Key Developments)

Valuation Changes

Fair Value: A$37.09 to A$43.33, representing an increase of around 16.8% in the central valuation point used in recent research.
Discount Rate: 7.56% to 7.39%, a small reduction that modestly lowers the required return used in updated models.
Revenue Growth: 5.09% to 3.82%, a lower growth assumption that points to more measured expectations for top line expansion.
Net Profit Margin: 2.23% to 2.40%, a slight increase in margin assumptions that reflects some efficiency or mix improvement over time.
Future P/E: 23.29x to 24.67x, a moderate uplift in the multiple applied to earnings, indicating a somewhat higher valuation being used in the updated work.

7 views

Key Takeaways

Operational and digital transformation initiatives are driving efficiency and margin gains, with leadership hires and digital health investments accelerating patient-focused, data-driven growth strategies.
Demographic trends and enhanced capacity in specialty care position Ramsay to capture higher-margin, recurring cases, supporting sustainable revenue and case mix improvements.
Sector-wide wage pressures, regulatory uncertainty in key regions, and structural industry shifts threaten profitability, demanding caution amid rising costs and underperforming assets.

Catalysts

About Ramsay Health Care

Owns and operates hospitals in Australia, and internationally.What are the underlying business or industry changes driving this perspective?

The multiyear transformation program, focused on operational efficiency, digital transformation, and "One Ramsay" scale advantages (e.g., centralized procurement, standardization, enhanced theater utilization), is beginning to show results and is expected to drive further improvements in net margins and EBIT in FY '26 and beyond.
Improved private health insurer negotiations in Australia for FY '25 and '26 have locked in higher revenue indexation in line with expected wage inflation, supporting higher revenue growth and better margin management as underlying cost pressures persist.
Population aging in Australia and other key markets is translating to rising demand for elective surgeries, chronic disease management, and rehabilitation, supporting long-term volume and revenue growth-evidenced by 2.7% private hospital admissions growth and above-3% growth in surgical/day admissions.
Expansion in procedural capacity (new theaters, cath labs, emergency departments) in Australia and efforts to strengthen specialty service lines (oncology, cardiology, orthopedics) position Ramsay to capture higher-margin cases and benefit from long-term shifts toward complex and recurring care, supporting top-line growth and improved case mix earnings quality.
Digital health investment and leadership hires (COO and CCO with strong global track records in healthcare and payor engagement) are accelerating initiatives in data-driven decision making, patient/provider journey integration, and value-based care models-all aimed at boosting operational excellence, patient retention, and expanded revenue streams over the coming years.

Ramsay Health Care Earnings and Revenue Growth

Ramsay Health Care Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Ramsay Health Care's revenue will grow by 5.0% annually over the next 3 years.
Analysts assume that profit margins will increase from 0.0% today to 2.2% in 3 years time.
Analysts expect earnings to reach A$454.0 million (and earnings per share of A$1.97) by about September 2028, up from A$6.8 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting A$533.0 million in earnings, and the most bearish expecting A$388 million.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 24.1x on those 2028 earnings, down from 1144.2x today. This future PE is lower than the current PE for the AU Healthcare industry at 57.1x.
Analysts expect the number of shares outstanding to grow by 0.36% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.33%, as per the Simply Wall St company report.

Ramsay Health Care Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Significant regulatory and political uncertainty in France, including low tariff indexation (only 0.5% for 2025) and fiscal pressure from the government, is resulting in hospital earnings failing to keep pace with inflation and grants being withdrawn-posing a continued risk to long-term revenue and profitability in Ramsay Santé.
Persistent sector-wide wage inflation and upcoming enterprise bargaining agreements, particularly in Australia and France, may not be fully matched by revenue indexation or reimbursement increases, squeezing net margins and adversely impacting earnings, especially if Fair Work Commission outcomes or union negotiations result in higher-than-anticipated wage outcomes.
The ongoing shift towards outpatient and telehealth care, and a reported decline in demand for acute mental health and inpatient services (notably within Elysium and mental health segments), indicates a secular industry trend that could structurally reduce demand for traditional hospital-based admissions-directly impacting patient volumes and long-term revenue growth.
High ongoing capital expenditure requirements and investment in digital transformation, paired with flat dividends and only modest underlying profit growth, suggest a risk that returns on invested capital may remain under pressure, particularly as major hospital expansions and tech upgrades may take years to deliver margin expansion-a concern for long-term net margin and earnings improvement.
Ramsay continues to experience operational challenges and margin pressure in public-private partnerships (e.g., Joondalup public campus with a new contract resulting in a $37 million annual EBIT headwind and lengthened patient stays), as well as slow or negative occupancy trends in certain UK and European assets (like Elysium), highlighting the risk of underperforming assets dragging down group profitability over the long term if not effectively mitigated.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of A$38.111 for Ramsay Health Care based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of A$54.0, and the most bearish reporting a price target of just A$32.8.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be A$20.6 billion, earnings will come to A$454.0 million, and it would be trading on a PE ratio of 24.1x, assuming you use a discount rate of 7.3%.
Given the current share price of A$33.84, the analyst price target of A$38.11 is 11.2% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Ramsay Health Care?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

RHC: Stable Profit Margins And Discount Rate Set To Support Share Strength